/£bzar3
UUID:682ADF84-SCEA-430:;81DRD-5C2EC2AC6ﬁseedacted 6W0“, \ \ M», £5: {—1 N0; 9500/3
TCGA-DB-A27K-o - 371’) N ; 650.?
“‘““l'l'llllllllllllllllllllll'llllllllllllllll'lll ill ' W, " w /
llllllll
Illlllllllllllllllllllllllllllllllll||l|l|ll|||llll|lllllll Ill

page 1 / 1

copy No . 4

Date

 

Examination: Histopathological examinatior

Internal invoice No. Cost of diagnostic procedure Examination No

Patient: XXX PESEL: XXX Age: Gender; F

Material: 1. Total organ resection JIeft breast?

Unit in charge:

Physician in charge:

Material collected on: Material received on:
Expected time of examination: up to 8 working days
Clinical diagnosis: Cancer of the left breast

 

Examination performed on:

r . . . :
Left breastiized 16.8 x 13.3 x 4.2 cm removed along with axillary tissues sized 8 x 4 x 3 cm and a skin ﬂap of 17.8 x 9.2 cm.

Tumour sized 4.3 x 2.3 x 2.7 cm found in the upper inner quadrant, 2.4 cm from the lower boundary, 0.6 cm from the base and
1.2 cm from the skin.

M‘ . l . . :

Carcinoma ductale invasivum NHGZ (3+2+1, 0 mitoses/10 HPF, visual area diameter 0.55 mm).

Reactio lymphocytaria peritumoralis. Mamilla sine laesionibus.

Numerous focuses of carcinoma ductale in situ (DCIS) found within tumour (solid type, with medium nuclear atypia
and comedo necrosis, 30% of the tumour).

Invasio carcinomatosa vasorum.

Mamilla sine laesionibus.

Normal parenchyma in the glandular tissue.

Axillary lymph nodes

Metastases carcinomatosae in lymphonodis (No II / XVII).

mmmﬂnﬂﬂﬂﬂamm:

Carcinoma ductale invasivum mammae sinistraei Invasive ductai carcinoma of the let! breast”?

Metastases carcinomatosae in lymphonodis axillae (No II / XVII). Cancer metastases in axillary lymph nodes (No ll/XVII)
(NHGZ, pTZ, lea).

Compliance validated by:
Examination performed on:

Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell
nuclei. HERZ protein stained with Ventana's Pathway HER-2/neu (485) Rabbit Monoclonal Antibody. Negative reaction in
invasive cancerous cells ( Score = 1+).

Compliance validated by:

 

Puma! Tumor bite

HIPAA
Prior

lIIOhS
C is

 

